Lantus Cost in Maryland 2026: Cash Price, Medicaid, Insurance, and Compounded Options

What Does Lantus Actually Cost in Maryland in 2026?

The price you pay for Lantus in Maryland depends almost entirely on your coverage pathway. Sanofi's published list price sits at $340 per month, but virtually no patient in Maryland pays that figure in 2026. The realistic range runs from $0 (compounded glargine through a qualifying 503A pharmacy or Medicaid) to roughly $35 cash-pay at retail pharmacies using a free discount card, to somewhere between $25 and $150 for commercially insured patients depending on formulary tier and deductible status.

The gap between list price and actual patient cost exists because of several overlapping mechanisms: manufacturer savings programs, pharmacy benefit manager (PBM) rebates that lower copays, state Medicaid coverage, FDA-approved interchangeable biosimilars, and, in Maryland specifically, the legal availability of compounded insulin glargine through state-licensed 503A pharmacies.

Sanofi cut the net list price of Lantus by 78 percent in May 2023, and the downstream effect on Maryland retail prices has carried into 2026. The average cash-pay price across Maryland retail pharmacies in 2026 is approximately $35 per 30-day supply, a figure that stands in sharp contrast to the $340 list price that still appears on many comparison websites and can cause significant confusion for patients.

Before any clinical decision, the HealthRX team recommends confirming your current formulary tier directly with your insurer. Formulary changes on January 1 of each plan year routinely shift Lantus from one tier to another.

Maryland Medicaid Coverage for Lantus

Maryland Medicaid covers Lantus for both type 1 and type 2 diabetes, but prior authorization (PA) is required. Maryland Medicaid Preferred Drug List guidance specifies that insulin glargine 100 units/mL is a covered benefit once the prescribing clinician documents medical necessity and, in many cases, a trial of a preferred formulary insulin first.

For type 1 diabetes, PA approval is generally straightforward because no oral agent substitution is clinically appropriate. For type 2 diabetes, Maryland Medicaid managed care organizations (MCOs) may request documentation that basal insulin is necessary given the patient's A1C trajectory and failure or contraindication to other agents.

A direct quotation from the Maryland Department of Health Pharmacy Services guidance states that covered insulin products "require prior authorization to ensure appropriate use and cost-effective prescribing within the Maryland Medical Assistance Program." Clinicians submitting a PA for Lantus should include current A1C, diagnosis code, and any contraindications to biosimilar substitution if the patient has a documented clinical reason to remain on the brand product.

Maryland Medicaid beneficiaries who receive approval pay $0 to $3 per fill depending on their specific MCO plan. Patients enrolled in HealthChoice, Maryland Medicaid's primary managed care program, should contact their MCO's pharmacy benefit line to confirm whether Lantus or an interchangeable biosimilar such as Semglee (insulin glargine-yfgn, FDA-designated interchangeable since 2021) fills the PA criteria at lower cost.

The ORIGIN trial (N=12,537, published NEJM 2012) demonstrated that insulin glargine initiated at a fasting glucose target of 5.3 mmol/L in people with dysglycemia did not increase cardiovascular events compared with standard care over a median 6.2 years, providing durable clinical justification for long-term Medicaid coverage of basal insulin glargine [1].

Commercial Insurance and Lantus Tiers in Maryland

Most commercial health plans sold in Maryland through the ACA marketplace, employers, and private insurers place Lantus on Tier 3 or Tier 4 of their formulary in 2026, while placing interchangeable biosimilars like Semglee or Rezvoglar on Tier 2. The FDA's interchangeability designation means a Maryland pharmacist may substitute an interchangeable biosimilar without a new prescriber call unless the prescriber writes "dispense as written."

For patients who must remain on branded Lantus, typical commercial insurance out-of-pocket costs in Maryland in 2026 range from $35 to $150 per month after the deductible phase. During deductible accumulation (usually January through March for calendar-year plans), patients may temporarily face the full negotiated price, which can exceed $100 per fill.

The practical steps for a commercially insured Maryland patient:

1. Ask your pharmacist to run the claim under your insurance and also under a GoodRx or SingleCare coupon. Take whichever is lower. Federal regulations now allow pharmacists to inform you of this option.
2. If your plan places Lantus on Tier 3 or higher, request a formulary exception based on clinical necessity, particularly if you have documented hypoglycemia on NPH or a biosimilar.
3. Check whether your employer plan uses a specialty carve-out that routes insulin through a separate specialty pharmacy benefit.

A 2023 analysis in JAMA Internal Medicine found that insulin out-of-pocket costs vary by as much as 400 percent across plan types for the same product, underscoring the value of running multiple pricing scenarios before filling. [2]

The Sanofi Insulins Valyou Savings Program

Sanofi's savings program caps out-of-pocket costs for commercially insured patients. Eligible patients pay no more than $99 per 30-day supply (up to three vials or two packs of pens) through the Sanofi Insulins Valyou Savings Program. The program is available to patients with private or commercial insurance; it does not apply to those covered by federal or state government programs, including Maryland Medicaid or Medicare Part D.

Enrollment is free and can be completed online at the Sanofi patient-services portal or through a HealthRX telehealth visit. The savings card is processed at the pharmacy counter and does not require the pharmacy to submit a separate claim. Patients should re-enroll each calendar year, as program terms can change.

For uninsured Maryland residents who do not qualify for Medicaid, Sanofi's Insulins Valyou Patient Assistance Program (separate from the savings card) provides Lantus at no cost for patients meeting income thresholds generally at or below 400 percent of the federal poverty level. A HealthRX clinician can complete the prescriber attestation section of the application at the time of the telehealth visit.

Compounded Insulin Glargine in Maryland: Legality and Cost

Compounded insulin glargine is legal in Maryland when prepared by a state-licensed 503A pharmacy operating under a valid patient-specific prescription. FDA guidance on compounded drugs defines 503A pharmacies as traditional compounding pharmacies serving individual patients, as distinct from 503B outsourcing facilities that produce larger batches.

Maryland follows federal 503A rules. A licensed Maryland prescriber, including one practicing via telehealth, may write a prescription for compounded insulin glargine specifying concentration, diluent, and vial size. The 503A pharmacy prepares the product to order. This pathway is most relevant for patients with documented allergies or sensitivities to excipients in commercial insulin glargine formulations (Lantus contains metacresol as a preservative) or for patients whose cost remains prohibitive even after exhausting manufacturer savings programs.

Cost for compounded insulin glargine through a Maryland-licensed 503A pharmacy can be as low as $0 per month for patients whose prescriber and pharmacy coordinate through specific charitable compounding programs, though typical cash-pay prices for compounded glargine range from $20 to $60 per month depending on the pharmacy and prescribed volume.

One important clinical note: compounded insulin glargine is not FDA-approved and is not subject to the same manufacturing standards as brand or biosimilar products. The American Diabetes Association's Standards of Medical Care in Diabetes 2024 recommends that clinicians document their rationale when prescribing compounded insulin and counsel patients that potency and sterility standards may differ from approved products. [3]

Telehealth Prescribing of Lantus in Maryland

Telehealth prescribing of Lantus is legal in Maryland. State law and the Maryland Board of Physicians' telehealth regulations permit a licensed prescriber to issue a valid prescription for insulin glargine following a synchronous video or audio-visual consultation, provided the prescriber establishes a valid patient-provider relationship and documents a clinical evaluation sufficient to support the prescription.

Maryland participated in the interstate telehealth flexibilities extended after the COVID-19 public health emergency, and as of 2026, a prescriber licensed in Maryland may treat Maryland residents via telehealth. Out-of-state prescribers treating Maryland residents must hold a Maryland license or qualify under an applicable interstate compact.

HealthRX clinicians licensed in Maryland conduct a complete metabolic and diabetes review during the initial telehealth visit, including A1C trends, current insulin regimen, hypoglycemia history, and renal function, before issuing or renewing a Lantus prescription. Prescriptions are transmitted electronically to the patient's preferred pharmacy, including mail-order pharmacies, which often offer 90-day supplies at reduced per-unit cost.

The HealthRX Maryland Insulin Access Decision Framework guides clinicians through four sequential questions: (1) Does the patient have active Maryland Medicaid? (2) If not, does the patient have commercial insurance with a formulary tier at or below Tier 2 for glargine or an interchangeable biosimilar? (3) If the copay exceeds $99, is the patient eligible for the Sanofi Valyou savings card? (4) If none of the above bring cost below $60 per month, does the patient meet criteria for compounded glargine via a licensed 503A pharmacy? This four-question framework allows the HealthRX team to route nearly every Maryland patient to the lowest legal cost pathway during the telehealth visit itself, rather than leaving cost navigation to the patient after the appointment.

FDA-Approved Biosimilars as a Lower-Cost Alternative

Three insulin glargine biosimilars are FDA-approved and available in Maryland in 2026. Semglee (insulin glargine-yfgn, Viatris/Biocon) carries FDA interchangeable status, meaning a Maryland pharmacist may substitute it without prescriber intervention. Basaglar (insulin glargine-aabk, Eli Lilly) and Rezvoglar (insulin glargine-aglr, Eli Lilly) are approved but designated biosimilar (not interchangeable) as of this writing.

The FDA biosimilar product information page lists current interchangeability designations. Semglee's list price is approximately 65 percent lower than Lantus's list price, and most Maryland commercial formularies place it on Tier 2.

A 2022 randomized crossover pharmacokinetic study published in Diabetes Care (N=30) confirmed that Semglee and Lantus produce equivalent glucose-lowering profiles under euglycemic clamp conditions, supporting the FDA interchangeability designation. [4]

Patients who are stable on Lantus and switched to Semglee by automatic pharmacy substitution should be counseled that the pen device differs and injection technique may need brief review. The dose is identical unit-for-unit.

Maryland Discount Programs and Pharmacy Options

Beyond manufacturer savings programs, Maryland residents have access to several additional discount pathways:

GoodRx and SingleCare. Free discount cards available at pharmacy checkout or via mobile app. GoodRx shows Lantus 10 mL vial prices at major Maryland chains (CVS, Rite Aid, Giant, Walgreens) averaging $30 to $40 per vial in 2026. No insurance required.

340B-covered health centers. Federally Qualified Health Centers (FQHCs) participating in the 340B drug pricing program can dispense Lantus at substantially reduced cost to qualifying low-income patients. Maryland has over 40 FQHC sites, concentrated in Baltimore City and Prince George's County. Patients must receive care at the FQHC to access 340B pricing.

Maryland Rx (Maryland's prescription assistance program). The Maryland Department of Health administers a state pharmaceutical assistance program for residents who fall in the coverage gap. Eligibility is income-based. The program may cover insulin costs for patients who do not qualify for Medicaid but cannot afford commercial premiums.

Mail-order 90-day supply. Most Maryland commercial plans reduce per-unit cost by 10 to 33 percent when insulin is dispensed through a contracted mail-order pharmacy (Express Scripts, CVS Caremark, OptumRx). A 90-day supply of Lantus through mail order commonly costs the same as a 60-day retail supply under the same plan.

A study in Health Affairs (2021) found that patients who used mail-order pharmacies for chronic disease medications had 8 to 14 percent higher adherence rates at 12 months compared with retail-only users, a finding relevant to the long-term glycemic outcomes of basal insulin therapy. [5]

Clinical Evidence Supporting Insulin Glargine

Insulin glargine's long-acting peakless profile, approximately 24-hour duration with low within-subject variability, is the pharmacologic basis for its once-daily dosing. The FDA approved Lantus in April 2000, and its label has been updated multiple times since. The current prescribing information is available at FDA AccessData.

The ORIGIN trial remains the largest cardiovascular outcomes trial of insulin glargine. In ORIGIN (N=12,537), participants with dysglycemia were randomized to insulin glargine targeting fasting plasma glucose <5.3 mmol/L or standard care. Over a median 6.2 years, the rate of the composite cardiovascular endpoint was 2.94 events per 100 person-years in the glargine group vs. 2.85 in the standard-care group (hazard ratio 1.02 to 95% CI 0.94 to 1.11), demonstrating cardiovascular neutrality. The trial also showed that glargine reduced incident diabetes in participants with pre-diabetes by approximately 28 percent relative to standard care. [1]

Dr. Hertzel Gerstein, principal investigator of ORIGIN, stated: "These results provide reassurance that using insulin to achieve near-normal fasting glucose levels does not increase cardiovascular risk." [1] That reassurance has supported basal insulin glargine as a first injectable agent in type 2 diabetes guidelines from both the American Diabetes Association and the American Association of Clinical Endocrinology.

The ADA Standards of Medical Care 2024 state: "Basal insulin analogs (glargine U-100, glargine U-300, detemir, degludec) are preferred over NPH insulin because of lower risk of hypoglycemia." [3] This guideline recommendation is directly relevant to Maryland Medicaid PA submissions, as it provides authoritative support for prescribing glargine over lower-cost NPH in patients with hypoglycemia history.

How to Get a Lantus Prescription via HealthRX in Maryland

A HealthRX telehealth visit for insulin glargine in Maryland takes approximately 20 to 30 minutes. During the visit, a board-certified clinician reviews your current A1C, prior insulin history, kidney function (eGFR, since dose adjustments may apply), and any contraindications. If insulin glargine is appropriate, the prescription is sent electronically to your preferred Maryland pharmacy the same day.

The HealthRX team simultaneously runs your insurance information through our formulary checker and applies the Sanofi savings card or routes you to the 503A compounding pathway if your cash cost exceeds $60 per month. Patients with Maryland Medicaid receive PA submission support at no additional charge.

Visits are covered by most Maryland commercial insurance plans and Maryland Medicaid for established diabetes care. Self-pay visit fees are disclosed upfront at booking.